ASCENDIS PHARMA A/S - ADR (ASND) Stock Analyst Ratings
NASDAQ:ASND • US04351P1012
225 USD
-5.21 (-2.26%)
At close: Feb 20, 2026
225 USD
0 (0%)
After Hours: 2/20/2026, 6:17:25 PM
ChartMill assigns a Buy % Consensus number of 88% to ASND. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 277.84. This target is 23.49% above the current price.
- ASND was analyzed by 24 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about ASND.
- In the previous month the buy percentage consensus was at a similar level.
- ASND was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-30 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-07 | TD Cowen | Reiterate | Buy -> Buy |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-11-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-10-17 | Raymond James | Initiate | Strong Buy |
| 2025-10-13 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-02 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-08 | UBS | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Stifel | Maintains | Buy -> Buy |
| 2025-08-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-06-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-06-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-05 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
ASCENDIS PHARMA A/S - ADR / ASND FAQ
What do analysts expect the price target to be for ASCENDIS PHARMA A/S - ADR (ASND)?
24 analysts have analysed ASND and the average price target is 277.84 USD. This implies a price increase of 23.49% is expected in the next year compared to the current price of 225.
Can you provide the consensus rating for ASCENDIS PHARMA A/S - ADR stock?
The consensus rating for ASCENDIS PHARMA A/S - ADR (ASND) is 88.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ASCENDIS PHARMA A/S - ADR stock?
The number of analysts covering ASCENDIS PHARMA A/S - ADR (ASND) is 24.